The SPDR S&P Biotech ETF (XBI) closed at $162.39 on August 29, 2026, declining 3.49% over the past 24 hours as selling pressure weighed on the biotech sector. The daily loss extended a modest weekly retreat, with the fund also down 2.00% over the past seven days.
Despite the recent pullback, XBI has posted a notable gain of 9.78% over the trailing 30-day period, reflecting a broader stretch of strength in biotech equities heading into late August.
The single-session drop represents a meaningful reversal from that monthly momentum, suggesting near-term volatility has picked up within the sector. Market capitalization data for the fund was not available as of the time of reporting.
XBI tracks an equal-weighted index of U.S.-listed biotechnology companies, making it sensitive to broad moves across small- and mid-cap names in the space. The fund's price action over the past month illustrates the sector's capacity for both rapid gains and sharp reversals.
